Acceleron Pharma Inc. (XLRN) Trading at $47.88 Forms Bullish Double Top

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

During 2018 Q3 the big money sentiment decreased to 1.03. That’s change of 0.44, from 2018Q2’s 1.47. 20 investors sold all, 43 reduced holdings as Acceleron Pharma Inc. ratio dropped. 43 increased holdings while 22 funds took holdings. Funds hold 42.72 million shares thus 9.61% more from 2018Q2’s 38.98 million shares.
Bnp Paribas Arbitrage Sa holds 2,175 shs or 0% of its capital. New York-based D E Shaw has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Barclays Pcl stated it has 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Eagle Asset accumulated 0.24% or 882,159 shs. Advisory Rech holds 0.03% or 34,760 shs. Moreover, Meeder Asset Management has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 123 shs. Neville Rodie Shaw Incorporated has invested 0.24% in Acceleron Pharma Inc. (NASDAQ:XLRN). Teacher Retirement Sys Of Texas holds 0% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN) for 4,317 shs. Millennium Limited Liability, New York-based fund reported 7,570 shs. Parametrica Mngmt Ltd accumulated 6,288 shs. 464,680 are owned by Northern Corp. Voya Invest Mngmt Ltd Liability Corp stated it has 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Rhumbline Advisers, a Massachusetts-based fund reported 36,577 shs. Tiaa Cref Ltd Liability Com has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 120,784 shs. Tower Research Cap Limited Liability Company (Trc) holds 27 shs or 0% of its capital.

Acceleron Pharma Inc. registered $2.55 million net activity with 0 buys and 3 sales since June 29, 2018. On Friday, June 29 MCLAUGHLIN KEVIN F had sold 25,000 shs worth $1.20 million.

The double top chart pattern of Acceleron Pharma Inc. (XLRN) has $51.23 PT or 7.00 % above today’s $47.88 share price. It has $2.21 billion MC. On Dec, 12 this chart pattern was announced by Finviz.com. $154.84 million more could be XLRN valuation at $51.23 share price.

The stock decreased 0.46% or $0.22 during the last trading session, hitting $47.88.Acceleron Pharma Inc. has volume of 244,948 shares. Since December 12, 2017 XLRN has risen 37.04% and is uptrending. The stock outperformed the S&P500 by 37.04%.

On February, 26 is anticipated Acceleron Pharma Inc. (NASDAQ:XLRN)’s earnings report, as reported by Faxor. Analysts have anticipation on stock’s earnings per share of $-0.67. That’s down 8.06 % from last year’s $-0.62 earnings per share. Wall Street now forecasts 6.35 % negative EPS growth despite Acceleron Pharma Inc. previous quarter’s EPS of $-0.63.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

A total of 4 analysts rate Acceleron Pharma (NASDAQ:XLRN) as follows: 2 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 50% are bullish. The firm has $75 highest and $40 lowest target. The avg target $57.50 is 20.09% above the last ($47.88) price. (NASDAQ:XLRN) has 6 ratings reports on Dec 12, 2018 according to StockzIntelligence. On Friday, June 29 the company was maintained by Credit Suisse. On Monday, September 10 the firm earned “Equal-Weight” rating by Morgan Stanley. On Friday, June 29 the stock has “Neutral” rating by Goldman Sachs. On Friday, July 13 Morgan Stanley downgraded the shares of XLRN in report to “Equal-Weight” rating. On Tuesday, July 10 the stock has “Neutral” rating by PiperJaffray. On Tuesday, September 18 the stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Overweight” rating by PiperJaffray.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news released briefly go to: Fool.com, Nasdaq.com, Businesswire.com, Profitconfidential.com or Seekingalpha.com. The titles are as follows: “Here’s Why Acceleron Pharma Inc. Lost 10.2% in July – The Motley Fool” released on August 04, 2018, “Week Ahead In Pharmaceuticals: 5 Stocks To Watch (OMER, BOLD, XLRN…) – Nasdaq” on September 29, 2018, “Acceleron to Participate in Two Upcoming Healthcare Investor Conferences – Business Wire” with a publish date: November 26, 2018, “An Explosive Move in XLRN Stock Is Now on the Horizon – Profit Confidential” and the last “Acceleron: Luspatercept New Data Is A Buy Signal – Seeking Alpha” with publication date: June 07, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.